Results 131 to 140 of about 15,932 (195)

Sodium-Glucose Cotransporter 2 Inhibitors in Alport Syndrome: Emerging Clinical Evidence and Mechanistic Insights. [PDF]

Kidney360
Miyata KN, Miner JH.
europepmc   +1 more source

Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5463-5475, July 2026.
ABSTRACT Cardiovascular‐kidney‐metabolic (CKM) syndrome is defined by the pathologic interconnections between obesity, diabetes, chronic kidney disease and cardiovascular disease. An important and underrecognized pathophysiologic factor underlying CKM syndrome is obesity‐induced aldosterone excess.
Evan Zeitler, Klara R. Klein, Ildiko Lingvay, Anthony Pick, Liana K. Billings   +4 more
wiley   +1 more source

SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications. [PDF]

Drugs Context
Manunta M, Bruno GM, Ferrantelli A, Ramirez RF, Nardi F.   +4 more
europepmc   +1 more source

Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5834-5847, July 2026.
ABSTRACT Aims To evaluate the associations between semaglutide initiation and long‐term skeletal outcomes in people with obesity, stratified by type 2 diabetes (T2D) status, using target trial emulation. Materials and Methods This retrospective cohort study used the TriNetX federated electronic health record network.
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Shao‐Chia Chen, Hao‐I Hsieh, Gideon Meyerowitz‐Katz, Yen‐Liang Liu, Pen‐Hua Su   +8 more
wiley   +1 more source

Research Progress of SGLT2 Inhibitors in the Treatment of Acute Heart Failure: A Narrative Review. [PDF]

Int J Gen Med
Wang X, Ning Y, Wang X, Li G, Wang X, Wu D.   +5 more
europepmc   +1 more source

GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6347-6357, July 2026.
ABSTRACT Aims Evidence on cardiovascular/renal outcomes associated with GLP‐1‐based therapies in type 1 diabetes (T1D) is limited. We examined the effects of GLP‐1‐based therapy on major clinical outcomes and safety, including diabetic ketoacidosis (DKA) and hypoglycemia risk, in adults with T1D in a large real‐world cohort.
Anastasios Tentolouris, Charalampos Filippatos, Nikolaos‐Iason Tepetes, Maria Gavriatopoulou, Evangelos Terpos, Alexandros Briasoulis, Kimon Stamatelopoulos, Theodosios Filippatos   +7 more
wiley   +1 more source

Protective efficacy of dapagliflozin against schistosomiasis mansoni-induced liver pathology: an in vivo study. [PDF]

Sci Rep
Hegazy MK, Masoud R, Othman BH, Alhusseiny SM.   +3 more
europepmc   +1 more source

Uncoupling Erythropoiesis from Cardiorenal Effects: SGLT2 Inhibition in Non-Diabetic Heart Failure. [PDF]

Medicina (Kaunas)
Măgureanu DC, Bocsan IC, Pop RM, Neag MA, Cozma A, Buzoianu AD.   +5 more
europepmc   +1 more source

<i>Candida glabrata</i> Prostatitis: A Rare Case in a Patient With Type 2 Diabetes Mellitus on Dapagliflozin Treatment. [PDF]

Case Rep Infect Dis
Torres García EG, Marcelo Calvo C, Navarro-Carrera P, Díez-Vidal A, Díaz-Pollán B.   +4 more
europepmc   +1 more source

Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations. [PDF]

Front Cardiovasc Med
Wang Z, Wang Y, Shangguan W, Li T.
europepmc   +1 more source